CM-CIC leads €6m in series-A for InFlectis BioScience

Other contributors include previous investors Go Capital and Participations Besançon. The deal specifies that investors provide €4.5m funding immediately, and have subscribed to a €1.5m investment option to be provided at a later stage, depending on pre-agreed conditions.

The fresh capital will enable InFlectis to keep making progress with its current flagship drug IFB-088 by financing its pre-clinical regulatory development and the first clinical tests on voluntary human subjects. The drug is targeted at curing neurodegenerative diseases.

Previous funding
In January 2015, InFlectis raised €1.75m in seed funding. BPI France had committed €300,000, while Go Capital and Participations Besancon each contributed €500,000. The rest of the funding came from the founders themselves. This first round of funding had allowed the company to perform several in-vivo studies with IFB-088.

Company
InFlectis BioScience is a private drug discovery company aiming at targeting and modulating interactions between proteins involved in key human pathophysiological processes.

Based in Nantes, it was founded in 2013 by scientists Philippe Guédat and Pierre Miniou.

People
Go Capital – Jérôme Guéret (managing partner).
Participations Besançon – Pierre Besançon (investment director).
CM-CIC Innovation – Emilie Lidome (deputy director).
Regimes Ventures – Taro Inaba (managing partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• France
• Healthcare
• Early-stage
• France
• Venture
• Credit Mutuel Equity (ex CM-CIC Investissement)